Reinhold Horlacher (Trenzyme GmbH)

Horlacher, Reinhold (Trenzyme GmbH 2010– Managing Director + Founder)

	Organisation	Trenzyme GmbH
	Group	Trenzyme (Group)
	Product	contract manufacturing (biologicals)
	Product 2	cell line development (research assays)

Trenzyme GmbH. (10/28/20). "Press Release: Successful Anniversary Year for Trenzyme – also with Corona. Constance-based Biotechnology Company Trenzyme Celebrates Its 20th Anniversary". Konstanz.

For 20 years, the Constance-based biotechnology company has been supplying researchers around the world with cell lines and proteins. Thanks to its high level of technical expertise, many years of experience and routine in dealing with new issues, trenzyme GmbH was able to react quickly to the corona virus this spring. With the production of SARS-CoV-2 proteins on a large scale and in very high qualtiy, the organization has since then been supporting corona research and COVID-19 vaccine development. In its anniversary year, the company continues to face new challenges and to develop continously.

Within the last two decades, the research service provider for recombinant proteins and cell lines has successfully established itself in this highly specialized field and has grown steadily. The team of around 20 people supplies leading pharmaceutical groups, academic institutes and biotechnology companies worldwide. The specifically developed products are used by customers to test the effect of drugs or to mark cancer cells to distinguish healthy from diseased cells. In this way, trenzyme’s products make an important contribution to the research and fight against widespread diseases such as Alzheimer’s diabetes, cancer, rheumatism and obesity. In addition, the cell lines and proteins produced are available in larger quantitites and in constant quality due to genetic engineering, in contrast to animal experiments.

“We have continuously developed our tailor-made services in order to be able to cover the increasing outsourcing trend of our customers”, explains founder and managing director Dr. Reinhold Horlacher, “ because more and more pharmaceutical companies want to concentrate on their own products and therefore outsource part of their research and development work”. In doing so, the managing director considered it important for the company to achieve steady growth from its own resources which is why he decided to dispense with venture capital.

In addition to the outsourcing trend, scientific expertise, innovative technologies and a high level of quality play an important role in the company’s success. the ISO 9001:2015 certified quality management in combination with a Laboratory Information Management System (LIMS) guarantee transparency and the highest quality standards.

Thanks to these strenghts and competencies, trenzyme was able to react quickly at the beginning of the year and was one of the first organizations in Europe to produce the corona virus surface protein, the SARS-CoV-2 Spike S1 (RBD) protein, which is very important for research, on a large scale. “In the meantime, we now produce many other SARS-CoV-2 proteins and supply them to numerous researchers around the world. They are working, for example, on the production of diagnostic tests for the virus or on the development if therapeutic agents,” Horlacher says.

To further support the global fight against the coronavirus, the company has established a GMP production cell line for vaccine development and has started initial efficacy studies for a nasal post-exposure vaccine (XPOVAX). Discussions are currently being held with cooperation partners, financiers and public authorities to rapidly advance this groundbreaking new development. This may be another important milestone in trenzyme’s history and a welcome, though self-made, gift to mark the company’s 20th anniversary. Managing Director Dr. Reinhold Horlacher is already looking forward to the next challenges and many more exciting years with his comany and his employees at the Constance site.

Conatct:

trenzyme GmbH
Lena Lögler
Online Marketing Manager
Byk-Gulden-Str. 2
78467 Konstanz
Email: lena.loegler@trenzyme.com
Phone: +49-7531-12290-0
Web: www.trenzyme.com